AnGes MG, Inc. is mainly engaged in the development of genetic medicines. The Company is segment the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo, hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2011, the Company had four consolidated subsidiaries. On September 1, 2011, the Company established a wholly owned subsidiary engaged in manufacturing and sales of healthcare products. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.